Pharmaceutical

Methylphenidate

Methyl 2-phenyl-2-(piperidin-2-yl)acetate

Evidence TierAWADA PROHIBITED

tuneTypical Dose

10–40 mg per day (prescription)

watchEffect Window

IR onset 30–60 min, duration 4–6 h. ER onset 1–2 h, duration 8–12 h.

lockCompliance

WADA PROHIBITED

Overview

Clinical Summary

Methylphenidate is a prescription stimulant used for ADHD and narcolepsy. It improves attention and executive function and reduces excessive daytime sleepiness through catecholamine reuptake inhibition.

Randomized trials show improved ADHD symptoms and functional outcomes in school and work settings. It also reduces excessive daytime sleepiness in narcolepsy. Minority research explores augmentation in depression and cognitive rehabilitation after brain injury, with mixed results. Benefits are well supported for indicated conditions, but side effects and misuse potential require clinical oversight.

Norepinephrine–dopamine reuptake inhibitor (NDRI) that blocks DAT and NET, increasing dopamine and norepinephrine in the prefrontal cortex and striatum to improve executive function and attention.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Highly effective at reducing core ADHD symptoms (hyperactivity, impulsivity, inattention) with a meta-analytic effect size of d=0.49 in children and adolescents

Secondary Outcomes

  • Modest improvements in working memory, episodic memory, and inhibitory control in healthy adults at therapeutic doses. Also used for treatment of narcolepsy

Safety

Contraindications and Interactions

Contraindications

  • Glaucoma
  • Pheochromocytoma
  • Severe anxiety or agitation
  • MAOI use within 14 days
  • Structural cardiac abnormalities
  • Hyperthyroidism
  • Tic disorders or Tourette syndrome

Side effects

  • Appetite suppression
  • Insomnia
  • Headache
  • Increased heart rate and blood pressure
  • Anxiety
  • Irritability
  • Stomach pain
  • Dry mouth

Interactions

  • MAOIs (hypertensive crisis)
  • Antihypertensives (antagonism)
  • Coumarin anticoagulants
  • Anticonvulsants
  • SSRIs/SNRIs
  • Caffeine and stimulants (additive CV risk)

Avoid if

  • History of substance abuse
  • Uncontrolled hypertension
  • Psychotic spectrum disorders
  • Pregnancy
  • Severe hepatic impairment

Evidence

Study-level References

methylphenidate-SRC-001Meta-analysis
Sourceopen_in_new

Faraone SV, Buitelaar J. "Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis." Eur Child Adolesc Psychiatry. 2010.

Population: Children and adolescents with ADHD

Key findings: Robust and statistically significant reductions in ADHD symptoms with effect sizes comparable to other stimulants.

Paper content

Robust and statistically significant reductions in ADHD symptoms with effect sizes comparable to other stimulants.

methylphenidate-SRC-002Umbrella review with re-estimated meta-analyses of randomized controlled trials.
Sourceopen_in_new

Gosling CJ, Garcia-Argibay M, De Prisco M, et al. Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. BMJ. 2025;391:e085875. doi:10.1136/bmj-2025-085875. PMID:41297970.

Population: Individuals across the lifespan with ADHD, including children, adolescents, and adults, drawn from 47 meta-analytic reports.

Dose protocol: Umbrella review covering 47 meta-analytic reports across pharmacological and non-drug ADHD interventions.

Key findings: Methylphenidate showed large effect sizes (SMD > 0.75) for ADHD symptom reduction in children and adolescents with moderate-to-high certainty. Tolerability was favorable with dropout risk about half that of placebo.

Notes: Most comprehensive cross-treatment comparison available. Confirms methylphenidate as first-line for pediatric ADHD.

Paper content

This BMJ umbrella review re-analyzed 47 meta-analytic reports covering 221 unique intervention-comparator-outcome combinations for ADHD. Methylphenidate showed large effect sizes (SMD > 0.75) for short-term ADHD symptom reduction in children and adolescents with moderate-to-high certainty. Treatment tolerability was favorable, with dropout risk about half that of placebo (RR = 0.50). Adults showed medium effect sizes for methylphenidate, atomoxetine, and CBT. The review provides the most comprehensive cross-treatment comparison available and confirms methylphenidate as a first-line pharmacological option for pediatric ADHD.

Guides

Setup

Help